Fake Ozempic, Medicare And A $1.1 Trillion Lilly: 10 Things Happening In Pharma

Health is the true wealth

While the tape argues about AI, the yen and whatever macro crisis comes next, healthcare has quietly become interesting again. Biotech is within spitting distance of its early-2021 highs, Lilly is getting comfortable in the trillion-dollar club, and European pharma is beginning to attract flows after a miserable run.

There isn't one grand thesis here. Instead, consider this our latest collection of observations from across pharma and biotech — some bullish, some less so, but all worth having on the radar.